Eileen P Scully

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5596172/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Considering how biological sex impacts immune responses and COVID-19 outcomes. Nature Reviews Immunology, 2020, 20, 442-447.	10.6	681
2	CXCL13 is a plasma biomarker of germinal center activity. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 2702-2707.	3.3	322
3	Sex Differences in HIV Infection. Current HIV/AIDS Reports, 2018, 15, 136-146.	1.1	128
4	Estrogen receptor-1 is a key regulator of HIV-1 latency that imparts gender-specific restrictions on the latent reservoir. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E7795-E7804.	3.3	121
5	NK Cells in HIV Disease. Current HIV/AIDS Reports, 2016, 13, 85-94.	1.1	114
6	Replicative fitness of transmitted HIV-1 drives acute immune activation, proviral load in memory CD4 ⁺ T cells, and disease progression. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E1480-9.	3.3	87
7	Follicular Dendritic Cells Retain Infectious HIV in Cycling Endosomes. PLoS Pathogens, 2015, 11, e1005285.	2.1	84
8	Sex-Based Differences in Human Immunodeficiency Virus Type 1 Reservoir Activity and Residual Immune Activation. Journal of Infectious Diseases, 2019, 219, 1084-1094.	1.9	73
9	Fungal brain infections. Current Opinion in Neurology, 2008, 21, 347-352.	1.8	62
10	Sex and gender differences in HIV-1 infection. Clinical Science, 2016, 130, 1435-1451.	1.8	62
11	Sex Differences in Neurocognitive Function in Adults with HIV: Patterns, Predictors, and Mechanisms. Current Psychiatry Reports, 2019, 21, 94.	2.1	54
12	Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. Annals of Oncology, 2018, 29, 2141-2142.	0.6	47
13	Human Immunodeficiency Virus Type 1 Persistence Following Systemic Chemotherapy for Malignancy. Journal of Infectious Diseases, 2017, 216, 254-262.	1.9	41
14	Sex and Gender Differences in Testing, Hospital Admission, Clinical Presentation, and Drivers of Severe Outcomes From COVID-19. Open Forum Infectious Diseases, 2021, 8, ofab448.	0.4	41
15	Long-term remission despite clonal expansion of replication-competent HIV-1 isolates. JCI Insight, 2018, 3, .	2.3	39
16	HIV-1-Mediated Downmodulation of HLA-C Impacts Target Cell Recognition and Antiviral Activity of NK Cells. Cell Host and Microbe, 2017, 22, 111-119.e4.	5.1	37
17	Reduced HIV-1 latent reservoir outgrowth and distinct immune correlates among women in Rakai, Uganda. JCI Insight, 2020, 5, .	2.3	32
18	Participant Perspectives in an HIV Cure-Related Trial Conducted Exclusively in Women in the United States: Results from AIDS Clinical Trials Group 5366. AIDS Research and Human Retroviruses, 2020, 36, 268-282.	0.5	21

EILEEN P SCULLY

#	Article	IF	CITATIONS
19	HIV Antibody Fc N-Linked Glycosylation Is Associated with Viral Rebound. Cell Reports, 2020, 33, 108502.	2.9	19
20	Elevated Levels of Microbial Translocation Markers and CCL2 Among Older HIV-1–Infected Men. Journal of Infectious Diseases, 2016, 213, 771-775.	1.9	17
21	Innate immune reconstitution with suppression of HIV-1. JCI Insight, 2016, 1, e85433.	2.3	16
22	Sex Differences in HIV Infection: Mystique Versus Machismo. Pathogens and Immunity, 2018, 3, 82.	1.4	10
23	Low Rate of Sex-specific Analyses in Presentations at the Conference on Retroviruses and Opportunistic Infections (CROI) Meeting, 2018: Room to Improve. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, e158-e160.	0.9	9
24	Impact of Tamoxifen on Vorinostat-Induced Human Immunodeficiency Virus Expression in Women on Antiretroviral Therapy: AIDS Clinical Trials Group A5366, The MOXIE Trial. Clinical Infectious Diseases, 2022, 75, 1389-1396.	2.9	9
25	Hidden in plain sight: sex and gender in global pandemics. Current Opinion in HIV and AIDS, 2021, 16, 48-53.	1.5	8
26	Protective HLA alleles are associated with reduced LPS levels in acute HIV infection with implications for immune activation and pathogenesis. PLoS Pathogens, 2019, 15, e1007981.	2.1	7
27	Sex-biased clinical presentation and outcomes from COVID-19. Clinical Microbiology and Infection, 2021, 27, 1072-1073.	2.8	7
28	Unlocking the complexity of HIV and Mycobacterium tuberculosis coinfection. Journal of Clinical Investigation, 2021, 131, .	3.9	6
29	Statistical analysis of single-copy assays when some observations are zero. Journal of Virus Eradication, 2019, 5, 167-173.	0.3	5
30	Just a Cut. New England Journal of Medicine, 2017, 376, 500-501.	13.9	4
31	Sex, gender and infectious disease. Nature Microbiology, 2022, 7, 359-360.	5.9	3
32	Challenges in optimizing preexposure prophylaxis development, engagement, and access for HIV prevention. Journal of Clinical Investigation, 2019, 129, 5071-5073.	3.9	2